Webinar Hub

7,111 upcoming
MedicalZoom

Topics › Medical & Clinical

EPNS Journal Club: Use of High-Efficacy Therapy in Children with Multiple Sclerosis to Prevent Long-Term Disability

Free

Length
1 hr
Platform
Zoom
Topic
Medical & Clinical

Get notified when the recording is available

We’ll email you once, when this recording is ready, with an unsubscribe link. See our privacy policy.

About this webinar

This retrospective cohort study evaluated the long-term impact of early high-efficacy monoclonal antibody therapy in pediatric-onset multiple sclerosis (POMS). Data from three international MS registries included 277 patients, of whom 108 initiated treatment with natalizumab, ocrelizumab, or rituximab before age 18, while 169 started between ages 20 and 22. Disability progression was assessed between ages 23 and 27 using EDSS scores. Patients treated during childhood demonstrated significantly less disability accumulation, with an EDSS increase 0.53 points lower than those treated in adulthood. The greatest benefit was observed in patients with moderate disability (EDSS 4.5–6.0). These findings provide Class II evidence supporting early initiation of high-efficacy therapies to improve long-term neurological outcomes in POMS patients.

Journal Link: https://www.neurology.org/doi/10.1212/WNL.0000000000218056?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

More Medical webinars 725

All Medical →

All Medical (725)